Iceni broadens glycoscience operations – Med-Tech Innovation

7 January 2022
09:59
Iceni Glycoscience (formerly Iceni Diagnostics) is to broaden the scope of its operations within the field of glycoscience (carbohydrate chemistry and biology) as the role of carbohydrates in human disease becomes increasingly apparent.
With mounting concerns about Coronavirus mutations and rising incidents of influenza (human, equine and avian), the need for new and improved diagnostics and therapeutic modalities to address infectious disease has risen. These need to be capable of producing earlier, faster, more accurate results – something which glycoscience methodologies offer by working uniquely at the initial binding stage of a virus. They have the potential to pick up on new variants or mutations quicker than tests which typically work by detecting viral nucleic acids or proteins, both of which require prior knowledge about the virus structure.
Iceni Glycoscience has been using glycoscience for diagnostic and therapeutic benefit since 2014, exploiting the natural biological function of glycans (complex sugars) as an alternative to protein or nucleic acid targets.
Glycoscience, however, is not limited to viruses. A rapidly expanding understanding of the glycobiology of other human and animal diseases, including cancer and autoimmunity is providing new points of intervention to impact on these conditions, using glycan targets or glycan-based drugs to affect the progress and outcomes of these diseases.
Dr Martin Stocks, CEO of Iceni Glycoscience, said: “The pharmaceutical world and, by default, society has become fixated with proteins or nucleic acids (DNA or RNA) as the main routes for developing diagnostics and therapeutics. However, there is another way – and, over the last few years, our work and academic partnerships have demonstrated quite convincingly why glycans represent an important alternative way forward.
“There is now an enormous buzz around the potential of glycoscience to deliver both diagnostic tests and new therapeutic interventions across a variety of applications in human and animal health. As well as driving our own internal programmes, we have the credibility and expertise within the sector to be able to offer our unique expertise to other companies working on their own projects – with the aim of enabling new products to get to market quicker for the benefit of all. Hence, we have decided to transition the name of the company from Iceni Diagnostics to Iceni Glycoscience to better represent our core focus and our broader service offerings.”
7 January 2022
09:59
MTI Subscribe

CONNECT WITH US
Contact Us
Media Kit
About Us
Med-Tech Expo

FOLLOW US
Twitter Med tech  linked in med tech   youtube med tech   Facebook med tech

RAPID NEWS GROUP PUBLICATIONS
Medical Plastics News
European Pharmaceutical Manufacturer
TCT Magazine
Manufacturing Quality

CORPORATE
Terms & Conditions
Privacy Policy
Part of Rapid News Group
© Rapid Medtech Communications Ltd. A Rapid News Group Company. All Rights Reserved

source